Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,2R)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropane-1-carboxamide
-
milnacipran
(2-chloro-6-methylpyrimidin-4-yl)butylamine
-
(2-chloro-6-methylpyrimidin-4-yl)cyclohexylamine
-
(2-chloro-6-methylpyrimidin-4-yl)cyclopropylmethylpropylamine
-
(2-chloro-6-methylpyrimidin-4-yl)decylamine
-
(2-chloro-6-methylpyrimidin-4-yl)dimethylamine
-
(2-chloro-6-methylpyrimidin-4-yl)ethylamine
-
(2-chloro-6-methylpyrimidin-4-yl)hexylamine
-
(2-chloro-6-methylpyrimidin-4-yl)octylamine
-
(2-chloro-6-methylpyrimidin-4-yl)propylamine
-
(2-chloro-6-methylpyrimidin-4-yl)tetradecylamine
-
(2E)-2-cyano-N-(3-[[(2E)-2-cyano-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]propyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide
-
-
(2E)-2-cyano-N-(3-[[(2E)-2-cyano-3-(4-hydroxyphenyl)prop-2-enoyl]amino]propyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide
-
-
(2E)-2-cyano-N-(3-[[(2E)-2-cyano-3-phenylprop-2-enoyl]amino]propyl)-3-(3,4-dihydroxyphenyl)prop-2-enamide
-
-
(2E,2'E)-N,N'-(2-hydroxypropane-1,3-diyl)bis[2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide]
-
-
(2E,2'E)-N,N'-(2-phenoxypropane-1,3-diyl)bis[2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide]
-
-
(2E,2'E)-N,N'-(2-propoxypropane-1,3-diyl)bis[2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide]
-
-
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-piperidine
-
paroxetine
(4-chloro-6-methylpyrimidin-2-yl)(1-cyclopropylmethylpropyl)amine
-
(4-chloro-6-methylpyrimidin-2-yl)-dimethylamine
-
(4-chloro-6-methylpyrimidin-2-yl)butylamine
-
(4-chloro-6-methylpyrimidin-2-yl)cyclohexylamine
-
(4-chloro-6-methylpyrimidin-2-yl)decylamine
-
(4-chloro-6-methylpyrimidin-2-yl)hexylamine
-
(4-chloro-6-methylpyrimidin-2-yl)octylamine
-
(4-chloro-6-methylpyrimidin-2-yl)propylamine
-
(4-chloro-6-methylpyrimidin-2-yl)tetradecylamine
-
(5Z)-3-(prop-2-en-1-yl)-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-(2H-chromen-3-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-(3,5-dichlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-(4-bromobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-(biphenyl-4-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-benzyl-5-[4-[3-(dimethylamino)propoxy]benzylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-ethyl-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-3-benzyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-3-benzyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2H-chromen-3-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2H-chromen-3-ylmethylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(2H-chromen-3-ylmethylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3,5-dichlorobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3,5-dichlorobenzylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(3,5-dichlorobenzylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(4-bromobenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(4-bromobenzylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(4-bromobenzylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(biphenyl-4-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(biphenyl-4-ylmethylidene)-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(biphenyl-4-ylmethylidene)-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[4-[3-(dimethylamino)propoxy]benzylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[4-[3-(dimethylamino)propoxy]benzylidene]-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[4-[3-(dimethylamino)propoxy]benzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine
-
mianserin
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro[2]benzofuran-5-carbonitrile
-
citalopram
10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenz[b,f]azepine
-
desipramine
2,5-bis(2-(dimethylamino)ethylamino)-1,4-benzoquinone
-
-
2,5-bis(2-(hydroxymethyl)anilino)-1,4-benzoquinone
-
-
2,5-bis(2-bromoanilino)-1,4-benzoquinone
-
-
2,5-bis(2-carboxyanilino)-1,4-benzoquinone
-
-
2,5-bis(3-bromopropylamino)-1,4-benzoquinone
-
-
2,5-bis(3-carboxyanilino)-1,4-benzoquinone
-
-
2,5-bis(3-hydroxyanilino)-1,4-benzoquinone
-
-
2,5-bis(3-methoxyanilino)-1,4-benzoquinone
-
-
2,5-bis(3-methoxypropylamino)-1,4-benzoquinone
-
-
2,5-bis(4-(hydroxymethyl)phenylamino)-1,4-benzoquinone
-
-
2,5-bis(4-carboxyanilino)-1,4-benzoquinone
-
-
2,5-bis(4-carboxybenzylamino)-1,4-benzoquinone
-
-
2,5-bis(4-hydroxyanilino)-1,4-benzoquinone
-
-
2,5-bis(4-hydroxybenzylamino)-1,4-benzoquinone
-
-
2,5-bis(4-methoxyanilino)-1,4-benzoquinone
-
-
2,5-bis(4-methoxybenzylamino)-1,4-benzoquinone
-
-
2,5-bis(hexylamino)-1,4-benzoquinone
-
-
2,5-bis(phenylamino)-1,4-benzoquinone
-
-
2,5-bis-(benzylamino)-1,4-benzoquinone
-
-
2-((8-chlorodibenzo(b,f)thiepin-10-yl)oxy)-N,N-dimethylethylamine
-
zotepine
2-(2-carboxyanilino)-1,4-naphthoquinone
-
-
2-(2-dimethylaminoethyl)-4-N-(didecylamino)-6-methylpyrimidine
-
2-(3-(hydroxymethyl)anilino)-1,4-naphthoquinone
-
-
2-(3-hydroxyanilino)-1,4-naphthoquinone
-
-
2-(4-(hydroxymethyl)anilino)-1,4-naphthoquinone
-
-
2-(4-hydroxyanilino)-1,4-naphthoquinone
-
-
2-(4-hydroxybenzylamino)-1,4-naphthoquinone
-
-
2-chloro-4-(2-dimethylaminopropylamine)-6-methylpyrimidine
-
2-chloro-5-methyl-4-(4-methylpiperazin-1-yl)pyrimidine
-
2-chloro-N-(4-methoxybenzyl)-6-methylpyrimidin-4-amine
-
2-cyano-3-(3,4-dihydroxyphenyl)acrylic acid 2-[2-cyano-3-(3,4-dihydroxyphenyl)acryloyloxy]butyl ester
-
IC50: 0.061 mM
2-cyano-3-(3,4-dihydroxyphenyl)acrylic acid 2-[2-cyano-3-(3,4-dihydroxyphenyl)acryloyloxy]ethyl ester
-
IC50: 0.042 mM
2-cyano-3-(3,4-dihydroxyphenyl)acrylic acid 2-[2-cyano-3-(3,4-dihydroxyphenyl)acryloyloxy]propyl ester
-
IC50: 0.038 mM
2-cyano-N-[2-[2-cyano-3-(3,4,5-trihydroxyphenyl)acryloylamino]ethyl]-3-(3,4,5-trihydroxyphenyl)acrylamide
-
IC50: 0.0017 mM
2-cyano-N-[2-[2-cyano-3-(3,4-dihydroxy-4-methoxyphenyl)acryloylamino]ethyl]-3-(3,4-dihydroxy-5-methoxyphenyl) acrylamide
-
IC50: 0.009 mM
2-cyano-N-[3-[2-cyano-3-(3,4,5-trihydroxyphenyl)acryloylamino]hexyl]-3-(3,4,5-trihydroxyphenyl)acrylamide
-
IC50: 0.006 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxy-5-methoxy-phenyl)acryloylamino]hexyl]-3-(3,4-dihydroxy-5-methoxyphenyl)acrylamide
-
IC50: 0.08 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxy-5-methoxy-phenyl)acryloylamino]pentyl]-3-(3,4-dihydroxy-5-methoxyphenyl)acrylamide
-
IC50: 0.008 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxy-5-methoxyphenyl)acryloylamino]butyl]-3-(3,4-dihydroxy-5-methoxyphenyl)acrylamide
-
IC50: 0.008 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxy-5-methoxyphenyl)acryloylamino]propyl]-3-(3,4-dihydroxy-5-meth-oxyphenyl)acrylamide
-
IC50: 0.005 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxyphenyl)acryloylamino]-2-hydroxypropyl]-3-(3,4-dihydroxyphenyl)acrylamide
-
IC50: 0.0051 mM
2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxyphenyl)acryloylamino]-propyl] 3-[4-(3-trifluoromethyl-3H-diazirin-3-yl)phenyl]acrylamide
-
-
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
-
nortriptyline
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-propan-1-amine
-
chlorpromazine
3-(4-azidophenyl)-2-cyano-N-[3-[2-cyano-3-(3,4-dihydroxyphenyl)acryloylamino]propyl]acrylamide
-
-
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
-
imipramine
3-(9-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
-
clomipramine
3-sulfo-N-(2-hydroxyethyl)-1,8-naphthalimide
-
3-[(5Z)-4-oxo-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(2H-chromen-3-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(3,5-dichlorobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(4-bromobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-(biphenyl-4-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[4-[3-(dimethylamino)propoxy]benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
4-(2-dimethylaminoethyl)-2-N-(didecylamino)-6-methylpyrimidine
-
4-(N,N-dimethyl-N-butyl-N-ethyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-(N,N-dimethyl-N-dodecyl-N-ethyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione bromide
-
-
4-(N,N-dimethyl-N-dodecyl-N-ethyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-(N,N-dimethyl-N-dodecyl-N-propyl)-4-aza-10-oxa-6-ethyltricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-(N,N-dimethyl-N-dodecyl-N-propyl)-4-aza-10-oxa-6-methyltricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-(N,N-dimethyl-N-dodecyl-N-propyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione bromide
-
-
4-(N,N-dimethyl-N-dodecyl-N-propyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-(N,N-dimethyl-N-octadecyl-N-ethyl)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione bromide
-
-
4-(N-methyl-N-ethylpiperidine)-4-aza-10-oxatricyclo[5.2.1]decane-3,5-dione methanesulfonate
-
-
4-amino-3-sulfo-N-(2-(dimethylamino)ethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-(piperazin-1-yl)ethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-aminobenzyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-aminoethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-carboxyethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-hydroxyethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-mercaptoethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(2-methoxyethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(3-aminobenzyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(3-hydroxyphenyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(3-hydroxypropyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(4-aminobenzyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(4-carboxybenzyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(4-hydroxybenzyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(4-hydroxyphenyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(4-methoxyphenyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(5-hydroxyhexyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(5-hydroxypentyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(carboxymethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-(phenethyl)-1,8-naphthalimide
-
4-amino-3-sulfo-N-benzyl-1,8-naphthalimide
-
4-amino-3-sulfo-N-phenyl-1,8-naphthalimide
-
4-azido-N-(2-[2-cyano-3-(3,4-dihydroxyphenyl)acryloylamino]-1-[[2-cyano-3-(3,4-dihydroxyphenyl)acryloylamino]methyl]ethyl)-2,3,5,6-tetrafluorobenzamide
-
-
4-chloro-6-methyl-2-(4-methylpiperazin-1-yl)pyrimidine
-
4-chloro-N-(4-methoxybenzyl)-6-methylpyrimidin-2-amine
-
4-sulfo-N-(2-hydroxyethyl)-1,8-naphthalimide
-
4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
-
haloperidol
5H-dibenz[b,f]azepine-5-carboxamide
-
carbamazepine
Arc/Arg3.1
enhances dynamin polymerization and GTPase activity. The activity-regulated cytoskeleton-associated protein, Arc, is an immediate-early gene product implicated in various forms of synaptic plasticity. Arc promotes endocytosis of AMPA type glutamate receptors and regulates cytoskeletal assembly in neuronal dendrites. Bacterially-expressed His6-Arc facilitates the polymerization of Dyn2 and stimulates its GTPase activity under physiologic conditions (37°C and 100 mM NaCl). At lower ionic strength Arc also stabilizes preformed Dyn2 polymers against GTP-dependent disassembly, thereby prolonging assembly-dependent GTP hydrolysis catalyzed by Dyn2. Analysis of recombinant full-length mouse Arc and of His6-tagged fragments, including Arc-N (residues 1-227), Arc-C (residues 228-396), and Arc-(DELTA195-214). At physiologic ionic strength, Arc facilitates Dyn2 self-assembly but does not prevent GTP-dependent Dyn2 disassembly, which is expected to suppress rather than activate endocytosis
-
beta,gamma-methyleneguanosine-5'-monophosphate
-
-
bis-tyrphostin
-
potent inhibitor of the phospholipid-stimulated GTPase activity of dynamin
Ca2+
-
inhibits dynamin I GTPase activity after stimulation by phosphorylation or by phospholipids but not after stimulation a glutathione S-transferase-SH3 fusion protein containing the SH3-domain of phosphoinositide 3-kinase
catechol-acrylamide
-
IC50: 0.0051 mM
cyclosporin A
treating BL-3 cells with 0.005 mM cyclosporine depletes mitochondrial dynamin-2
dynamin inhibitory peptide
-
-
-
fluvoxamine
-
a noncompetitive inhibitor of dynamin I with respect to GTP and a competitive inhibitor with respect to L-phosphatidylserine
guanylyl-iminodiphosphate
-
-
heterotrimeric G protein betagamma subunit complex
-
methyl 2-phenyl-2-(2-piperidyl)acetate
-
methylphenidate
mitochondrial division inhibitor
-
selectively inhibits the mitochondrial division dynamin, is a selective inhibitor of the mitochondrial division dynamin-related GTPase Drp1, and has no effect on either basal or assembly-stimulated rates of GTP hydrolysis for dynamin-1
-
myristyl trimethyl ammonium bromide
-
standard inhibitor of dynamin I
N'-(2-chloro-6-methylpyrimidin-4-yl)ethane-1,2-diamine
-
N'-(4-Chloro-6-methylpyrimidin-2-yl)-ethane-1,2-diamine
-
N-(2-diethylaminoethyl)-2-methoxy-5-methylsulfonyl-benzamide
-
tiapride
N-(2-hydroxyethyl)-1,8-naphthalimide
-
N-benzyl-2-chloro-6-methylpyrimidin-4-amine
-
N-benzyl-4-chloro-6-methylpyrimidin-2-amine
-
N-decyl-N'-(2-dimethylaminoethyl)-pyrimidine-4,6-diamine
-
N-dodecyl-N'-(2-dimethylaminoethyl)pyrimidine-4,6-diamine
-
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan-1-amine
-
fluoxetine
N-methyl-9,10-ethanoanthracene-9(10H)-propanamine
-
maprotiline
N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoyl-benzamide
-
sulpiride
N-[2-[[(2E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]-1-([[(2E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]methyl)ethyl]benzamide
-
-
N1-(4-chloro-6-methylpyrimidin-2-yl)-N3,N3-dimethylpropane-1,3-diamine
-
N2-(2-dimethylaminoethyl)-6-methyl-N4-octadecylpyrimidine-2,4-diamine
-
N2-(2-dimethylaminoethyl)-6-methyl-N4-propylpyrimidine-2,4-diamine
-
N2-(2-dimethylaminoethyl)-6-methyl-N4-tetradecylpyrimidine-2,4-diamine
-
N2-(2-dimethylaminoethyl)-N4-decyl-6-methylpyrimidine-2,4-diamine
-
N2-(2-dimethylaminoethyl)-N4-hexyl-6-methylpyrimidine-2,4-diamine
-
N2-(2-dimethylaminoethyl)-N4-octyl-6-methylpyrimidine-2,4-diamine
-
N2-benzyl-N4-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N2-butyl-N4-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N2-cyclohexyl-N4-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N2-cyclopropylmethyl-N4-(2-dimethylamin-ethyl)-6-methyl-N2-propylpyrimidine-2,4-diamine
-
N2-decyl-N4-(2-dimethylaminoethyl)pyrimidine-2,4-diamine
-
N2-dodecyl-N4-(2-dimethylaminoethyl)-pyrimidine-2,4-diamine
-
N2-sec-butyl-N4-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-6-methyl-N2-octadecylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-6-methyl-N2-propylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-6-methyl-N2-tetradecylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-N2-decyl-6-methylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-N2-hexyl-6-methylpyrimidine-2,4-diamine
-
N4-(2-dimethylaminoethyl)-N2-octyl-6-methylpyrimidine-2,4-diamine
-
N4-Benzyl-N2-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N4-butyl-N2-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N4-cyclohexyl-N2-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
N4-cyclopropylmethyl-N2-(2-dimethylamin-ethyl)-6-methyl-N2-propylpyrimidine-2,4-diamine
-
N4-decyl-N2-(2-dimethylaminoethyl)pyrimidine-2,4-diamine
-
N4-dodecyl-N2-(2-dimethylaminoethyl)pyrimidine-2,4-diamine
-
N4-sec-butyl-N2-(2-dimethylaminoethyl)-6-methylpyrimidine-2,4-diamine
-
oligomeric beta-amyloid
-
induces dynamin 1 cleavage and depletion, 0.001 mM of A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 cleavage
-
sec-butyl-(2-chloro-6-methylpyrimidin-4-yl)amine
-
sec-butyl-(4-chloro-6-methylpyrimidin-2-yl)amine
-
sertraline
-
a mixed type inhibitor with respect to both GTP and L-phosphatidylserine
[(5Z)-4-oxo-5-(quinoxalin-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(2,1,3-benzothiadiazol-5-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(2,1,3-benzoxadiazol-5-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(2H-chromen-3-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(3,5-dichlorobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(4-bromobenzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-(biphenyl-4-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[(5-chloro-1-benzothiophen-3-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[(6,8-dichloro-4-oxo-4H-chromen-3-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[4-[3-(dimethylamino)propoxy]benzylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[2-(2-chloro-6-methylpyrimidin-4-ylamino)ethyl]carbamic acid tert-butyl ester
-
[2-(4-chloro-6-methylpyrimidin-2-ylamino)ethyl]carbamic acid tert-butyl ester
-
dynasore
-
interferes in vitro with Drp1 (the mitochondrial dynamin) activity of dynamin 2, acts as a potent inhibitor of endocytic pathways known to depend on dynamin by rapidly blocking coated vesicle formation; interferes in vitro with the GTPase activity of dynamin1, acts as a potent inhibitor of endocytic pathways known to depend on dynamin by rapidly blocking coated vesicle formation; interferes in vitro with the GTPase activity of dynamin 2, acts as a potent inhibitor of endocytic pathways known to depend on dynamin by rapidly blocking coated vesicle formation
dynasore
-
noncompetitive inhibitor of dynamin GTPase activity
dynasore
-
specific inhibitor of dynamin GTP hydrolysis
dynasore
dynamin specific inhibitor
dynasore
a dynamin inhibitor
dynasore
dynamin specific inhibitor
heterotrimeric G protein betagamma subunit complex
-
oligomerization of dynamin prevents inhibition
-
heterotrimeric G protein betagamma subunit complex
-
oligomerization of dynamin prevents inhibition
-
additional information
-
rhodadyns are a class of small molecule inhibitors of dynamin GTPase activity
-
additional information
fragment-based in silico screening against dynamin I GTPase activity identified the 1,8-naphthalimide framework as a potential scaffold for the design of new inhibitors targeting the GTP binding pocket of dynI. Structure-based design, synthesis and subsequent optimization resulted in the development of a library of 1,8-naphthalimide derivatives. Development of optimised GTP-competitive lead Naphthaladyn compound for the further development of naphthalimide-based dynI GTPase inhibitor. Molecular docking and molecular modelling representation of the predicted binding pose of naphthalimide 4-amino-3-sulfo-N-(2-aminoethyl)-1,8-naphthalimide within the GTP binding pocket of dynI, crystal structure, PDB ID 3ZYCS
-
additional information
computational approach of binding site identification, docking, and interaction energy calculations to design a library of aminopyrimidine analogues targeting site-2 of the pleckstrin homology (PH) domain. Synthesis and evaluation of pyrimidine-based inhibitors of dynamin I GTPase activity, competitive inhibition at the pleckstrin homology domain, overview. The optimized analogues show low micromolar inhibition against both dynamin I and CME and off-target effects at the cholecystokinin, dopamine D2, histamine H1 and H2, melanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and serotonin receptors. No inhibition by (4-chloro-6-methylpyrimidin-2-yl)ethylamine at 0.3 mM
-
additional information
-
development of quinone analogues as dynamin GTPase inhibitors, docking study and molecular modelling, overview. No or poor inhibition by 2,5-bis(2-methylanilino)-1,4-benzoquinone, 2,5-bis(2-methoxyanilino)-1,4-benzoquinone, 2,5-bis(3-(hydroxymethyl)phenylamino)-1,4-benzoquinone, 2,5-b+F49is(2-hydroxyethylamino)-1,4-benzoquinone, 2,5-bis(3-hydroxypropylamino)-1,4-benzoquinone, 2,5-bis(4-hydroxybutylamino)-1,4-benzoquinone, 2,5-bis(2-methoxyethylamino)-1,4-benzoquinone, 2,5-bis(2-(methylthio)ethylamino)-1,4-benzoquinone, 2,5-bis(2-chloroethylamino)-1,4-benzoquinone, 2,5-bis(2-bromoethylamino)-1,4-benzoquinone, 2,5-bis(3-chloropropylamino)-1,4-benzoquinone, 2,5-bis(3-pyridylmethylamino)-1,4-benzoquinone, 2,5-bis(4-methylbenzylamino)-1,4-benzoquinone, 2,5-bis(4-fluorobenzylamino)-1,4-benzoquinone, 2,5-bis(4-bromobenzylamino)-1,4-benzoquinone, 2,5-bis(4-chlorobenzylamino)-1,4-benzoquinone, 2,5-bis(phenethylamino)-1,4-benzoquinone, 2,5-bis(ethylamino)-1,4-benzoquinone, 2,5-bis(propylamino)-1,4-benzoquinone, 2,5-bis(butylamino)-1,4-benzoquinone, 2,5-bis(pentylamino)-1,4-benzoquinone, 2,5-bis(isopentylamino)-1,4-benzoquinone, 2,5-bis(allylamino)-1,4-benzoquinone, 2-(2-hydroxyethylamino)-1,4-naphthoquinone, 2-(3-hydroxypropylamino)-1,4-naphthoquinone, 2-(anilino)-1,4-naphthoquinone, 2-(3-carboxyanilino)-1,4-naphthoquinone, 2-(4-carboxyanilino)-1,4-naphthoquinone, 2-(benzylamino)-1,4-naphthoquinone, and 2-(4-methoxybenzylamino)-1,4-naphthoquinone
-
additional information
-
depolarization of primary neurons includes direct association of receptor-type protein tyrosine phosphatase PTP-NP with dynamin-1 within 30 s. This association results in significant inhibition of dynamin-1 GTPase activity (about 75% inhibition). Mutation within the phosphatase domain of PTP-NP (PTP-NP(D947A)) abolishes the direct interaction of PTP-NP with dynamin-1 and fails to inhibit dynamin-1 GTPase activity
-
additional information
-
human Drp1 is knocked down in HeLa cells by the specific siRNA
-